His entrepreneurial journey emerged naturally from his scientific work. Recognizing that groundbreaking ideas needed commercial pathways to reach patients, he co-founded BIND Therapeutics, a biotechnology company dedicated to advancing targeted nanoparticles for drug delivery. The company’s innovative approach attracted significant attention, but financial challenges eventually led to its acquisition by Pfizer—a reminder of both the difficulty and necessity of bringing medical technologies to market.
